China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical study for its pipeline drug candidate, ALMB-0168. The drug is set to be assessed as a treatment for acute ischemic stroke.
ALMB-0168: A Monoclonal Antibody for Neurological Conditions
ALMB-0168, a connexin 43-targeted monoclonal antibody, is an in-house development of CSPC’s subsidiary, AlaMab Therapeutics Inc. The drug is under development for the treatment of acute spinal cord injury, ischemic stroke, and a variety of other neurological diseases. Preclinical studies have demonstrated that ALMB-0168 can significantly reduce bone and joint pain in animals and improve the pathological condition of animal cartilage tissue, offering a new potential therapy for the fundamental treatment of osteoarthritis. The drug received an orphan drug designation (ODD) in the US in 2018 for its use in acute spinal cord injury, an indication for which it has completed Phase I clinical trials in Australia. Additionally, it has previously earned clinical trial approval in China for assessment in treating osteoarthritis.- Flcube.com
